Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad4HIV: HIV Vaccine Strategies
NCT03408262Phase 1Completed
- Sponsor
- Imperial College London
- Start
- Oct 2017
- Primary completion
- Feb 2020
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of Ad4-EnvCN54 in human immunodeficiency virus infection (HIV) (8 arms), sponsored by Imperial College London. Primary endpoints: Number of Participants With Mucosal Binding IgG Antibodies to HIV CN54gp140 Antigen, Number of Participants With Severe or Greater (Grades 3-4) Adverse Reactions During the Study and 1 more. Started Oct 2017; status: completed.
02
Drugs
Ad4-EnvCN54
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03408262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03408262.